TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading for March 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD for March 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 2,358 | 0 | 4,717 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 18.38 | 2,358 | 43,340 | 2,974 | 5.3 K to 3 K (-44.22 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 2,358 | 0 | 5,332 | 3 K to 5.3 K (+79.29 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 1,179 | 0 | 2,358 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 17.88 | 1,179 | 21,078 | 1,388 | 2.6 K to 1.4 K (-45.93 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 1,179 | 0 | 2,567 | 1.4 K to 2.6 K (+84.94 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Option Exercise | M | 0.00 | 872 | 0 | 1,746 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Sell | S | 17.89 | 457 | 8,177 | 5,746 | 6.2 K to 5.7 K (-7.37 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Buy | M | 0.00 | 872 | 0 | 6,203 | 5.3 K to 6.2 K (+16.36 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 660 | 0 | 1,321 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Sell | S | 17.88 | 287 | 5,131 | 11,295 | 11.6 K to 11.3 K (-2.48 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Buy | M | 0.00 | 660 | 0 | 11,582 | 10.9 K to 11.6 K (+6.04 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 943 | 0 | 1,887 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Sell | S | 17.88 | 943 | 16,859 | 0 | 943 to 0 (-100.00 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Buy | M | 0.00 | 943 | 0 | 943 | 0 to 943 |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 265 | 0 | 531 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 747 | 0 | 1,495 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 17.88 | 91 | 1,627 | 7,051 | 7.1 K to 7.1 K (-1.27 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 17.88 | 257 | 4,595 | 7,142 | 7.4 K to 7.1 K (-3.47 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 265 | 0 | 7,399 | 7.1 K to 7.4 K (+3.71 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 747 | 0 | 7,134 | 6.4 K to 7.1 K (+11.70 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,179 | 0 | 2,358 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 17.88 | 571 | 10,208 | 4,445 | 5 K to 4.4 K (-11.38 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,179 | 0 | 5,016 | 3.8 K to 5 K (+30.73 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 1,297 | 0 | 2,594 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 17.89 | 1,297 | 23,206 | 0 | 1.3 K to 0 (-100.00 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 1,297 | 0 | 1,297 | 0 to 1.3 K |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 2,441 | 0 | 2,444 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 19.20 | 2,441 | 46,867 | 2,974 | 5.4 K to 3 K (-45.08 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 2,441 | 0 | 5,415 | 3 K to 5.4 K (+82.08 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 738 | 0 | 738 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 19.49 | 738 | 14,383 | 1,388 | 2.1 K to 1.4 K (-34.71 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 738 | 0 | 2,126 | 1.4 K to 2.1 K (+53.17 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Option Exercise | M | 0.00 | 880 | 0 | 883 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Sell | S | 19.50 | 461 | 8,989 | 5,331 | 5.8 K to 5.3 K (-7.96 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Buy | M | 0.00 | 880 | 0 | 5,792 | 4.9 K to 5.8 K (+17.92 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 952 | 0 | 953 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Sell | S | 19.49 | 952 | 18,554 | 0 | 952 to 0 (-100.00 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Buy | M | 0.00 | 952 | 0 | 952 | 0 to 952 |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,190 | 0 | 1,191 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 19.49 | 576 | 11,226 | 3,837 | 4.4 K to 3.8 K (-13.05 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,190 | 0 | 4,413 | 3.2 K to 4.4 K (+36.92 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 714 | 0 | 715 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 19.50 | 714 | 13,922 | 0 | 714 to 0 (-100.00 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 714 | 0 | 714 | 0 to 714 |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 1,166 | 0 | 3,498 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 19.38 | 705 | 13,663 | 1,388 | 2.1 K to 1.4 K (-33.68 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Payment of Exercise | F | 19.38 | 461 | 8,934 | 2,093 | 2.6 K to 2.1 K (-18.05 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 1,166 | 0 | 2,554 | 1.4 K to 2.6 K (+84.01 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 1,049 | 0 | 3,148 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Payment of Exercise | F | 19.38 | 455 | 8,818 | 10,922 | 11.4 K to 10.9 K (-4.00 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Buy | M | 0.00 | 1,049 | 0 | 11,377 | 10.3 K to 11.4 K (+10.16 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,399 | 0 | 4,198 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Payment of Exercise | F | 19.38 | 677 | 13,120 | 3,223 | 3.9 K to 3.2 K (-17.36 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,399 | 0 | 3,900 | 2.5 K to 3.9 K (+55.94 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 2,098 | 0 | 6,297 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 19.28 | 1,108 | 21,362 | 0 | 1.1 K to 0 (-100.00 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Payment of Exercise | F | 19.28 | 990 | 19,087 | 1,108 | 2.1 K to 1.1 K (-47.19 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 2,098 | 0 | 2,098 | 0 to 2.1 K |